Jazz Pharmaceuticals FY Conference Summary Company Overview - **Company**: Jazz Pharmaceuticals (NasdaqGS:JAZZ) - **Date**: March 12, 2026 - **Key Speakers**: Philip Johnson (CFO), Jack Spinks (Head of Investor Relations) Core Industry Insights Financial Performance - **2025 Revenue**: Record revenue growth of 5%, driven by: - **Xywav**: 12% growth - **Epidiolex**: 9% growth - **Modeyso**: Strong initial uptake - **Consecutive Growth**: 21st consecutive year of revenue growth [3][4] Pipeline Developments - **Zepzelca**: Positive data in first-line maintenance small cell lung cancer in combination with atezolizumab - **Zanidatamab**: Unprecedented overall survival results extending beyond 2 years in first-line GEA [3][4] - **Acquisition**: Chimerix acquisition for dordaviprone, expected to yield over $200 million in tax savings [4] 2026 Guidance - **Revenue Forecast**: $4.25 billion - $4.5 billion, aiming for 22nd consecutive year of growth [4][5] Key Product Insights Xywav and Sleep Franchise - **Performance**: Continued growth in idiopathic hypersomnia and narcolepsy markets, with Xywav showing strong patient retention and safety benefits [15][17] - **Market Dynamics**: Anticipated competition from orexin agonists, but Xywav expected to remain complementary rather than competitive [20][23] Epidiolex and Epilepsy - **Market Position**: Strong IP runway with ANDA settlements extending to late 2030s; growth opportunities in adult patient populations [24][25] - **Patient Support**: Implementation of Nurse Navigator program to improve patient experiences and treatment adherence [25][27] Oncology Portfolio - **Modeyso**: Strong uptake with potential peak sales of $500 million in the US; ongoing evaluation of patient demographics and treatment duration [29][33] - **Zepzelca**: Anticipated to become standard of care in first-line maintenance setting, with expected revenue dynamics influenced by competitive landscape [43][44] Strategic Focus Areas Corporate Development - **Investment Strategy**: Focus on existing marketed products and pipeline, with plans to expand into new rare disease areas [10][11] - **Acquisition Strategy**: Targeting post-proof of concept investments in rare diseases, leveraging existing expertise [12] Future Growth Opportunities - **Oncology Expansion**: Plans to explore additional indications for zanidatamab and potential partnerships for HER2-targeted therapies [41][42] - **Research Development**: Transitioning to a fully integrated biopharma company with ongoing phase 1 assets in NRAS and KRAS programs [46] Additional Considerations - **Market Trends**: Ongoing interest in orexin agonists and their potential impact on existing therapies; Jazz positions itself as a complementary player in the market [19][20] - **Patient-Centric Approach**: Emphasis on improving patient outcomes and experiences across all therapeutic areas, particularly in epilepsy and oncology [25][27][43] This summary encapsulates the key points from the Jazz Pharmaceuticals FY Conference, highlighting the company's financial performance, product insights, strategic focus, and future growth opportunities.

Core Viewpoint - Hemlo Mining Corp. has appointed Jason Banducci as Vice President of Corporate Development & Investor Relations, aiming to enhance its strategic growth and market presence in the gold mining sector [1]. Group 1: Executive Appointment - Jason Banducci brings nearly 15 years of experience in corporate strategy, capital markets, mergers and acquisitions, and investor relations within the global mining sector [1]. - Prior to joining Hemlo Mining, Banducci held a senior executive role at a U.S.-focused gold producer, where he led a significant acquisition that increased the company's market capitalization from approximately $200 million to over $1 billion [1]. - Banducci's career includes being a founding executive at a gold exploration company and advising mining companies on various strategic transactions during his time in investment banking [1]. Group 2: Company Strategy and Vision - In his new role, Banducci will oversee corporate development, strategic initiatives, capital markets strategy, investor relations, and corporate communications [1]. - The company aims to grow into a leading Canadian mid-tier gold producer, focusing on maximizing the value of the Hemlo Gold Mine's existing infrastructure and pursuing aggressive brownfields exploration [1]. - Hemlo Mining recently acquired the Hemlo Gold Mine from Barrick Mining Corp. for up to US$1.1 billion, which has produced approximately 25 million ounces of gold since 1985 [1].

Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million in 2025, representing a 27% increase compared to the previous year [17] - The company reported a GAAP net loss of $38.6 million for 2025, compared to a net earnings of $73.9 million in 2024 [18] - For the fourth quarter of 2025, total revenue was $211.6 million, a 21% increase year-over-year [13] Business Line Data and Key Metrics Changes - Revenues from four growth products (Qelbree, Proquarius, Zurzuvae, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales of $17.3 million for its first year [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [7] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [6] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by over 150% [8] Company Strategy and Development Direction - The company is focused on corporate development and exploring strategic opportunities to strengthen its position in the CNS market through revenue-generating products and late-stage pipeline candidates [11] - Supernus aims to continue growing its core business despite the loss of exclusivity on Trokendi XR and Oxtellar XR [4] - The company plans to maintain a diversified portfolio of growth products to mitigate reliance on any single product [78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving total revenues of $840 million to $870 million for 2026, with expectations of $45 million to $70 million in net sales from ONAPGO [20] - The company anticipates combined R&D and SG&A expenses to range from $620 million to $650 million for 2026 [20] - Management highlighted the importance of resolving supply constraints for ONAPGO to meet demand and clear backlogs [29] Other Important Information - The company had approximately $309 million in cash equivalents and marketable securities as of December 31, 2025, down from $454 million in 2024 [19] - Supernus is actively working on R&D programs, including trials for SPN-820 and SPN-817, with data expected in 2027 [74] Q&A Session Summary Question: ONAPGO sales guidance and supplier capacity - Management confirmed that the current supplier can meet the sales guidance of $45 million to $70 million for ONAPGO through 2026, with a second supplier expected to come online in 2027 [23] Question: ONAPGO demand and backlog clearance - Management stated that the current supplier will help clear the backlog and meet ongoing demand throughout 2026 [29] Question: R&D prioritization post-Sage acquisition - Management indicated that early-stage assets will undergo preclinical work, and prioritization will be based on market opportunity and ROI [30] Question: Pricing expectations for ONAPGO - Management estimated that the average annual cost for ONAPGO could be around $100,000 per patient, depending on usage [38] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net deductions for ONAPGO to be in the range of 20% to 30%, typically higher in Q1 [67] Question: Commercial strategy for Zurzuvae - Management emphasized the need to build market awareness and confidence among physicians for Zurzuvae, while also focusing on both existing and new prescribers [60][62]

ROUYN-NORANDA, Quebec, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB: ABMBF) is very pleased to announce the appointment of Mr. Dany Cenac Robert to the position of Vice-President, Communications and Corporate Development. A strategic partner of the Corporation since 2018, Mr. Cenac Robert possesses in-depth knowledge of Abcourt's assets and vision. With over 20 years of experience in strategic communications and financial markets, he notably ...

You can find original article here WealthManagement. Subscribe to our free daily WealthManagement newsletters. The Wealth Consulting Group, a Las Vegas-based hybrid registered investment advisor and wealth management platform with more than $10 billion in assets under advisement, has hired Jason Ehrlich as CFO and head of corporate development.  Ehrlich, a former managing director and head of investments at Emigrant Partners, has been a strategic advisor to the firm for years and joined its advisory ...

Core Viewpoint - Liberty Gold Corp. has appointed Brad Ralph as Senior Vice President of Corporate Development, bringing over twenty years of experience in corporate development and investment banking, particularly in the mining sector [1][2]. Company Overview - Liberty Gold is focused on developing open pit oxide deposits in the Great Basin of the United States, which is known for its large-scale gold projects suitable for open-pit mining [4]. - The company is advancing the Black Pine Project in southeastern Idaho, which is a past-producing, Carlin-style gold system with significant resource potential and strong economic viability [4]. Executive Profile - Brad Ralph has a robust background in corporate development and investment banking, having served as CEO of Accelera Capital Inc. and held senior roles at various financial institutions [2][3]. - His expertise includes managing acquisition and sale transactions, sourcing funding solutions, and leading due diligence processes, with a notable track record in public markets and equity financing [3]. Leadership Statement - Jon Gilligan, President and CEO of Liberty Gold, expressed enthusiasm about Brad Ralph's appointment, highlighting his extensive experience in M&A transactions and project financing as critical for the company's growth [4].

Core Points - Pasinex Resources Limited has announced significant corporate developments, including the acquisition of the Sarıkaya zinc project, a change in financial year-end, updates on board nominations, progress on private placement financing, and the granting of stock options [1] Acquisition of Sarıkaya Zinc Project - The acquisition of the Sarıkaya zinc project in Türkiye has been completed, with Pasinex Arama now holding all outstanding shares of Aydın Teknik. The project features 30%-50% high-grade, carbonate-hosted zinc mineralization and is located near the Pinargozu mine [2] - The acquisition consolidates Pasinex's operations in Türkiye, as it now controls 100% of both the Pinargozu and Sarıkaya projects [2] Change in Financial Year-End - The company has changed its financial year-end from December 31 to March 31 to align its reporting cycle with industry peers. A transitional report will cover a fifteen-month period from January 1, 2025, to March 31, 2026 [3] Board Nomination and AGM - Dr. Mehmet Kömürcü has been nominated for election to the Board at the upcoming Annual General Meeting (AGM). He brings extensive experience in corporate governance and mining [4] - The AGM is scheduled for November 21, 2025, with a record date for voting set as October 17, 2025 [5] Private Placement Financing Update - The company has received strong investor support for its private placement financing, with over CAD $1.2 million in subscriptions out of a CAD $2.15 million offering. The financing is expected to close soon [6] Grant of Stock Options - Pasinex has granted 2,500,000 stock options to directors, officers, and key employees, which vest immediately and are exercisable at $0.075 per share [7] Management Comment - The Executive Chairman highlighted the transformative nature of recent developments, emphasizing the strategic control over two zinc projects and the positive outlook for growth and exploration [9]

Core Viewpoint - Cboe Global Markets has appointed Prashant Bhatia as Executive Vice President, Head of Enterprise Strategy & Corporate Development, effective September 2, 2025, to enhance its growth strategy and industry leadership [1][2]. Group 1: Appointment Details - Prashant Bhatia will collaborate with Cboe's executive leadership to refine the company's business strategy and identify growth opportunities [2]. - Craig Donohue, CEO of Cboe, emphasized Bhatia's valuable addition to the leadership team, highlighting his understanding of the competitive landscape and financial decision-making skills [2][3]. Group 2: Background of Prashant Bhatia - Bhatia has over 30 years of experience in the financial services sector, previously leading Enterprise Strategy & Corporate Development at TD Ameritrade for 11 years [3]. - He has been advising Cboe's management and working closely with its board of directors since December 2023 [3]. Group 3: Company Overview - Cboe Global Markets is recognized as the world's leading derivatives and securities exchange network, providing trading solutions across multiple asset classes globally [4]. - The company is committed to building a trusted and inclusive global marketplace to support sustainable financial futures [4].

Core Insights - Celestica Inc. has appointed Chris Colpitts to its Board of Directors, enhancing its leadership team as it continues to grow [1][3] - Mr. Colpitts brings 20 years of experience in technology, media, and telecommunications, with a strong background in investment banking and private equity [2] - The Board of Directors will now consist of 9 members following this appointment [4] Company Overview - Celestica is a leader in design, manufacturing, hardware platform, and supply chain solutions, partnering with top brands across various sectors including Aerospace and Defense, Communications, and HealthTech [5] - The company focuses on delivering solutions for complex challenges, leveraging global expertise throughout the product development process [5]

Core Insights - THOR Industries, Inc. has appointed Seth Woolf as Head of Corporate Development & Investor Relations, aiming to enhance long-term corporate initiatives and capital markets communications [1][2] - Woolf brings over 15 years of investment industry experience, particularly in the recreational vehicle sector, which will aid THOR in navigating market dynamics and supporting growth [2] Company Overview - THOR Industries is the largest manufacturer of recreational vehicles globally, owning several operating subsidiaries [3]